Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.

@article{Esteva2002PhaseIS,
  title={Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.},
  author={Francisco J. Esteva and Vicente Valero and Daniel J. Booser and Laura T Guerra and James Murray and Lajos Pusztai and Massimo Cristofanilli and B. J. Arun and B Esmaeli and Herbert A. Fritsche and Nour Sneige and Terry L. Smith and Gabriel N Hortobagyi},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2002},
  volume={20 7},
  pages={1800-8}
}
PURPOSE To evaluate the safety and efficacy of weekly docetaxel plus trastuzumab in women with HER-2-overexpressing metastatic breast cancer. Efficacy was correlated with serum HER-2 extracellular domain (ECD) levels. PATIENTS AND METHODS Thirty women with metastatic breast cancer were treated with weekly docetaxel and trastuzumab as first- or second-line therapy. Both docetaxel 35 mg/m(2)/wk and trastuzumab 2 mg/kg/wk were delivered in 4-week cycles consisting of three weekly treatments… CONTINUE READING
197 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 197 extracted citations

Similar Papers

Loading similar papers…